RS
CTXR icon

R Squared’s Citius Pharmaceuticals CTXR Stock Holding History

R Squared’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.67K Buy
+11,033
New +$7.47K ﹤0.01% 507

Other funds holding CTXR

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MFS
Miller Financial Services Marshall, Michigan $124M AUM 17.62% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
AAG
Asset Advisory Group Kinnelon, New Jersey $229M AUM

R Squared's CTXR Position: Q2 2026 in Review

R Squared opened a new position in Citius Pharmaceuticals (CTXR) in Q2 2026: 11,033 shares worth $6.67K. The stake represents ﹤0.01% of the portfolio and ranks #507 among its holdings.

43 funds tracked by Wall St. Rank hold CTXR as of Q2 2026.

  • R Squared held 11,033 shares of Citius Pharmaceuticals worth $6.67K as of Q2 2026.
  • Citius Pharmaceuticals was a new R Squared position in Q2 2026.
  • Citius Pharmaceuticals made up ﹤0.01% of R Squared's portfolio in Q2 2026, its #507 holding.
  • 43 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q2 2026.

Based on R Squared's 13F filing for Q2 2026, filed 5 Aug 2026.